Stem cell–derived models to improve mechanistic understanding and prediction of human drug‐induced liver injury
Year: 2016
Type: review
Abstract: Current preclinical drug testing does not predict some forms of adverse drug reactions in humans. Efforts at improving predictability of drug-induced tissue injury in humans include using stem cell technology to generate human cells for screening for adverse effects of drugs in humans. The advent of induced pluripotent stem cells means that it may ultimately be possible to develop personalized toxicology to determine interindividual susceptibility to adverse drug reactions. However, the complexity of idiosyncratic drug-induced liver injury means that no current single-cell model, whether of primary liver tissue origin, from liver cell lines, or derived from stem cells, adequately emulates what is believed to occur during human drug-induced liver injury. Nevertheless, a single-cell model of a human hepatocyte which emulates key features of a hepatocyte is likely to be valuable in assessing potential chemical risk; furthermore, understanding how to generate a relevant hepatocyte will also be critical to efforts to build complex multicellular models of the liver. Currently, hepatocyte-like cells differentiated from stem cells still fall short of recapitulating the full mature hepatocellular phenotype. Therefore, we convened a number of experts from the areas of preclinical and clinical hepatotoxicity and safety assessment, from industry, academia, and regulatory bodies, to specifically explore the application of stem cells in hepatotoxicity safety assessment and to make recommendations for the way forward. In this short review, we particularly discuss the importance of benchmarking stem cell-derived hepatocyte-like cells to their terminally differentiated human counterparts using defined phenotyping, to make sure the cells are relevant and comparable between labs, and outline why this process is essential before the cells are introduced into chemical safety assessment. (Hepatology 2017;65:710-721).
Source: Hepatology
DOI: 10.1002/hep.28886
Authors: Christopher Goldring, Daniel J. Antoine, Frank Bonner, Jonathan Crozier, Chris Denning, Robert J. Fontana, Neil A. Hanley, David C. Hay, Magnus Ingelman‐Sundberg, Satu Juhila, Neil Kitteringham, Beatriz Silva‐Lima, Alan Norris, Chris Pridgeon, James A. Ross, Rowena Sison Young, Danilo Tagle, Belen Tornesi, Bob van de Water, Richard J. Weaver, Fang Zhang, B. Kevin Park
Institutions: University of Liverpool, University of Nottingham, University of Michigan, Michigan Medicine, Manchester Academic Health Science Centre, University of Manchester, MRC Centre for Regenerative Medicine, University of Edinburgh, Karolinska Institutet, Orion Corporation (Finland), University of Lisbon, National Institutes of Health, National Center for Advancing Translational Sciences, AbbVie (United States), Leiden University, Institut de Recherches Internationales Servier (France)
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: green
Funders: Wellcome Trust, European Federation of Pharmaceutical Industries and Associations, British Heart Foundation, Heart Research UK, Stem Cells for Safer Medicines, European Commission, National Centre for the Replacement, Refinement and Reduction of Animals in Research, Vetenskapsrådet, Medical Research Council, Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: Stem cell screening of human nutrient-gene interactions at the epigenetic level, G1809243133, Centre for Drug Safety Science (CDSS), A novel system for perfusion and real-time analysis of single hESC-derived cardiomyocytes, G3407826557, G3418652168, Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury, New in vitro models of long QT syndrome by coupling induced pluripotency and cardiomyocyte differentiation, Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC), A hub for Engineering and exploiting the stem cell niche, MRC Centre for Regenerative Medicine, Detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems, G6500720415, G7112513775, G7162305877, The development of 3-dimensional implantable liver organoids, Deep molecular phenotyping of myotonic dystrophy (DM1) hiPSC-cardiomyocytes to facilitate risk stratification and drug evaluation, An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century, Coupling gene targeted reporters with fully automated compound library screening to mature hPSC-cardiomyocytes, Michigan Hepatotoxicity Clinical Research Network Renewal
OpenAlex ID: W2519164774
